Answers are grounded in this paper and cite their sources.
identifies patients with high-risk cancers and reduced tumor myeloid infiltration. MYC therefore regulates glycosylation to enable tumor immune evasion. We conclude that disialyl-T is a glycoimmune checkpoint ligand. Thus, disialyl-T is a candidate for antibody-based checkpoint blockade, and the disialyl-T synthase ST6GALNAC4 is a potential enzyme target for small molecule-mediated immune therapy.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: